128 related articles for article (PubMed ID: 37139723)
1. p53 Oligomerization Domain Mutants: A New Class of Mutants That Retain "License to Kill".
Stieg D; Casey K; Murphy ME
Cancer Discov; 2023 May; 13(5):1046-1048. PubMed ID: 37139723
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.
Choe JH; Kawase T; Xu A; Guzman A; Obradovic AZ; Low-Calle AM; Alaghebandan B; Raghavan A; Long K; Hwang PM; Schiffman JD; Zhu Y; Zhao R; Lee DF; Katz C; Prives C
Cancer Discov; 2023 May; 13(5):1250-1273. PubMed ID: 37067901
[TBL] [Abstract][Full Text] [Related]
3. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program.
Gencel-Augusto J; Su X; Qi Y; Whitley EM; Pant V; Xiong S; Shah V; Lin J; Perez E; Fiorotto ML; Mahmud I; Jain AK; Lorenzi PL; Navin NE; Richie ER; Lozano G
Cancer Discov; 2023 May; 13(5):1230-1249. PubMed ID: 37067911
[TBL] [Abstract][Full Text] [Related]
4. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
6. Li-Fraumeni syndrome: a p53 family affair.
Iwakuma T; Lozano G; Flores ER
Cell Cycle; 2005 Jul; 4(7):865-7. PubMed ID: 15917654
[TBL] [Abstract][Full Text] [Related]
7. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
9. A functionally inactive p53 Li-Fraumeni syndrome mutant.
Hao M; Finlay CA; Lozano G
Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
[TBL] [Abstract][Full Text] [Related]
10. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
11. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
12. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways.
Meneghetti BV; Wilson R; Dias CK; Cadore NA; Klamt F; Zaha A; Ferreira HB; Monteiro KM
Biochimie; 2022 Jul; 198():141-154. PubMed ID: 35367578
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of transcriptional activity of mutant p53 tumor suppressor protein through stabilization of tetramer formation by calix[6]arene derivatives.
Kamada R; Yoshino W; Nomura T; Chuman Y; Imagawa T; Suzuki T; Sakaguchi K
Bioorg Med Chem Lett; 2010 Aug; 20(15):4412-5. PubMed ID: 20605095
[TBL] [Abstract][Full Text] [Related]
14. Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.
Sherif ZA; Sultan AS
Cancer Biol Ther; 2013 Jan; 14(1):29-38. PubMed ID: 23114650
[TBL] [Abstract][Full Text] [Related]
15. p53 expression in three separate tumours from a patient with Li-Fraumeni's syndrome.
King P; Craft AW; Malcolm AJ
J Clin Pathol; 1993 Jul; 46(7):676-7. PubMed ID: 8157761
[TBL] [Abstract][Full Text] [Related]
16. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
[TBL] [Abstract][Full Text] [Related]
18. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
[TBL] [Abstract][Full Text] [Related]
19. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutants in the tower of babel of cancer progression.
Bisio A; Ciribilli Y; Fronza G; Inga A; Monti P
Hum Mutat; 2014 Jun; 35(6):689-701. PubMed ID: 24449472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
